StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.73+0.02 (+0.05%)

Close on Nov 18, 2026Market cap $27.98BP/E –Yield –

Roivant Sciences Priovant Therapeutics — Basic Ownership Stake by Quarter

Priovant Therapeutics — Basic Ownership Stake (%)

Periods

Roivant Sciences Priovant Therapeutics — Basic Ownership Stake: 71.0% in Q2 FY2026, down 2.0 pts from a year earlier. That is the lowest of the 15 quarters on record here.

Latest, Q2 FY2026
71.0%
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
-2.0 pts
73.0% in Q2 FY2025
History
15 quarters
Since Q4 FY2021
Sources
15
Documents cited below

Where the Q2 FY2026 figure comes from

“|| Priovant | 71 | % | 65 | %”

Source: Form 10-Q (roiv-20260930.htm, filed 2026-11-09) ↗

Joint venture formed with Pfizer Inc. developing LISRAYA (brepocitinib).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPriovant Therapeutics — Basic Ownership Stake (%)Year on yearSource
Q2 FY2026CQ3 2026Sep 30, 202671.0%-2.0 ptsForm 10-Q (roiv-20260930.htm, filed 2026-11-09) ↗
Q1 FY2026CQ2 2026Jun 30, 202671.0%–Form 10-Q (roiv-20260630.htm, filed 2026-08-06) ↗
Q4 FY2025CQ1 2026Mar 31, 202672.0%–Form 10-K (roiv-20260331.htm, filed 2026-05-20) ↗
Q3 FY2025CQ4 2025Dec 31, 202573.0%–Form 10-Q (roiv-20251231.htm, filed 2026-02-06) ↗
Q2 FY2025CQ3 2025Sep 30, 202573.0%–Form 10-Q (roiv-20250930.htm, filed 2025-11-10) ↗
Q1 FY2024CQ2 2024Jun 30, 202475.0%0.0 ptsForm 10-Q (ef20030921_10q.htm, filed 2024-08-09) ↗
Q4 FY2023CQ1 2024Mar 31, 202475.0%0.0 ptsForm 10-K (ef20026301_10k.htm, filed 2024-05-30) ↗
Q3 FY2023CQ4 2023Dec 31, 202375.0%0.0 ptsForm 10-Q (ef20015327_10q.htm, filed 2024-02-13) ↗
Q2 FY2023CQ3 2023Sep 30, 202375.0%0.0 ptsForm 10-Q (ef20012491_10q.htm, filed 2023-11-13) ↗
Q1 FY2023CQ2 2023Jun 30, 202375.0%0.0 ptsForm 10-Q (brhc20057263_10q.htm, filed 2023-08-14) ↗
Q4 FY2022CQ1 2023Mar 31, 202375.0%0.0 ptsForm 10-K (brhc20054745_10k.htm, filed 2023-06-28) ↗
Q3 FY2022CQ4 2022Dec 31, 202275.0%–Form 10-Q (brhc10047697_10q.htm, filed 2023-02-13) ↗
Q2 FY2022CQ3 2022Sep 30, 202275.0%–Form 10-Q (brhc10044005_10q.htm, filed 2022-11-14) ↗
Q1 FY2022CQ2 2022Jun 30, 202275.0%–Form 10-Q (d383218d10q.htm, filed 2022-08-15) ↗
Q4 FY2021CQ1 2022Mar 31, 202275.0%–Form 10-K (d307489d10k.htm, filed 2022-06-28) ↗

Breakdown

What makes up priovant Therapeutics — Basic Ownership Stake

Cite this data

StockData. (2026). Roivant Sciences Priovant Therapeutics — Basic Ownership Stake (%), quarterly Q4 FY2021–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/own-priovant-basic

See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?